Reply  by Cronenwett, J.L. & Seeger, J.
LETTERS TO THE EDITORRegarding “A new approach to carotid angioplasty
and stenting with transcervial occlusion and
protective shunting: Why it may be a better carotid
artery intervention”
Our method for achieving flow reversal to prevent emboli
during CAS via a cervical approach (J Vasc Surg 2004;39:994-
1002) is similar to one described by Parodi et al1 to achieve the
same ends via a transfemoral approach. We had acknowledged this
in an early draft of our article. Although the Parodi device is cited
in the references of the published version, direct reference in the
body of the text was omitted because of limitations on space.
David Chang, MD
Stanford University School of Medicine
San Jose, Calif
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Regarding “Aortofemoral bypass in young patients
with premature atherosclerosis: Is superficial femoral
vein superior to Dacron?”
Morasch et al used the term “superficial femoral vein” in their
article, “Aortofemoral bypass in young patients with premature
atherosclerosis: Is superficial femoral vein superior to Dacron?” (J
Vasc Surg 2004;40:17-23). This terminology should not be used
in a medical publication.
Caggiati et al1 argued that the unauthorized term “superficial
femoral vein” should not be used for the femoral vein, which is,
without doubt, a deep vein. Also, “superficial femoral vein” is not
in the Terminologica Anatomica.
This same mistake was made by Modrall et al,2 who used the
term in their article, “Comparison of superficial femoral vein and
saphenous vein as conduits for mesenteric arterial bypass.”
A common anatomic terminology is the foundation for a
common language in phlebologic sciences. Further, such a com-
mon language is important for investigation of the vascular system
and for accurate diagnosis and correct treatment.
It is unfortunate that the above misusage was overlooked by
the editor and reviewer of such a fine journal as Journal of Vascular
Surgery. We hope that in the future more effort will be made for
better reference.
Geun Eun Kim, MD, Professor
Bae Joo Yul, Medical student
Department of Vascular Surgery, Asan Medical Center
University of Ulsan, College of Medicine
Seoul, Korea
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Reply
The editors thankDrs Kim and Yul for pointing out the proper
terminology that should have been used in the 2 papers published
in the Journal concerning use of femoral and popliteal vein seg-
ments for arterial reconstructive procedures. Both of these papers
are from the vascular surgery group at the University of Texas
Southwestern, who pioneered these techniques at a time when the
femoral vein was still commonly termed the “superficial femoral
vein.” Subsequent usage of this incorrect term has persisted, and
indeed was not corrected by the editors during the review process
for these 2 recent papers. We completely agree with Drs Kim and
Yul that a common language is important for accurately commu-
nicating new scientific information.
J. L. Cronenwett, MD
Lebanon, NH
J. Seeger, MD
Gainesville, Fla
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Regarding “Floating thoracic aortic thrombus in
‘protein S’ deficient patient”
We read with interest the report by Hazirolam et al (J Vasc
Surg 2004;40:381) describing a floating thoracic aortic thrombus
in a woman with protein C deficiency. The authors report that she
was treated with warfarin, but no mention is made of whether a
prior treatment with heparin was carried out. It is known that
protein C and, in particular, protein S deficiency may be predispos-
ing conditions for occurrence of acute arterial thrombosis.1 War-
farin decreases the production not only of vitamin K–dependent
clotting factors, but also of protein C, an endogenous anticoagu-
lant factor. Protein S acts as a cofactor permitting the inhibitory
function of protein C, which is fully dependent on protein S to
express its anticoagulant activity.2 At the beginning of warfarin
therapy, protein C and factor VII rapidly drop, whereas factor X
and prothrombin levels decrease in 3 to 9 days. The difference in
kynetics—eg, factor VII and protein C have a short half-life (about
6-8 hours), prothrombin has a longer one (approximately 100
hours), and factors IX and X have an intermediate half-life—may
lead to a transitory hypercoagulative status, particularly during the
first 12 to 26 hours of warfarin administration.3 We have described
a fatal case of acute thorombosis of abdominal aorta in a female
patient shortly after starting warfarin therapy without previously
being treated with heparin for the onset of atrial fibrillation.4 The
observation that protein C and protein S deficiency may predispose
to warfarin-induced skin necrosis and thrombosis, however, does
not mandate that their levels always be measured before starting
oral anticoagulant therapy. The rarity of this and other genetic
trombophilic associations5 and their possible complications, in
fact, makes this approach impractical. However, to prevent possi-
